Patents Assigned to Agensys, Inc.
  • Antibody drug conjugates (ADC) that bind to CD37 proteins
    Patent number: 9925273
    Abstract: Antibody drug conjugates (ADC's) that bind to CD37 protein and variants thereof are described herein. CD37 exhibits a distinct and limited expression pattern in normal adult tissue(s), and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention in some embodiments provide a therapeutic composition for the treatment of cancer.
    Type: Grant
    Filed: July 30, 2014
    Date of Patent: March 27, 2018
    Assignee: AGENSYS, INC.
    Inventors: Daniel Sousa Pereira, Faisal Hayat Malik, Josh Snyder, Leslie Renee Butterworth, Ssucheng Jeff Hsu, Peng Yang, Claudia Isabel Guevara
  • Antibody drug conjugates (ADC) that bind to 158P1D7 proteins
    Patent number: 9926376
    Abstract: Antibody drug conjugates (ADC's) that bind to 158P1D7 protein and variants thereof are described herein. 158P1D7 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in glioblastoma, lung cancer, bladder cancer, and breast cancer. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Grant
    Filed: March 30, 2016
    Date of Patent: March 27, 2018
    Assignees: Agensys, Inc., Seattle Genetics Inc.
    Inventors: Robert Kendall Morrison, Zili An, Karen Jane Meyrick Morrison, Josh Snyder, Xiao-Chi Jia
  • ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO FLT3 PROTEINS
    Publication number: 20180037657
    Abstract: Antibody drug conjugates (ADC's) that bind to FLT3 protein and variants thereof are described herein. FLT3 exhibits a distinct and limited expression pattern in normal adult tissue(s), and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Application
    Filed: March 9, 2016
    Publication date: February 8, 2018
    Applicant: AGENSYS, INC.
    Inventors: Nandini RUDRA-GANGULY, Christine LOWE, Faisal Hayat MALIK, Sung Ju MOON, Josh SNYDER, Hector AVINA, Cyrus VIRATA, Linnette CAPO, Gao LIU
  • ANTIBODIES AND MOLECULES DERIVED THEREFROM THAT BIND TO STEAP-1 PROTEINS
    Publication number: 20170275377
    Abstract: Antibodies and molecules derived therefrom that bind to novel STEAP-1 protein, and variants thereof, are described wherein STEAP-1 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, STEAP-1 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer.
    Type: Application
    Filed: March 2, 2017
    Publication date: September 28, 2017
    Applicant: AGENSYS, INC.
    Inventors: Aya JAKOBOVITS, Soudabeh ETESSAMI, Pia M. CHALLITA-EID, Juan J. PEREZ-VILLAR, Karen J. MORRISON, Xiao-Chi JIA, Mary FARIS, Jean GUDAS, Arthur B. RAITANO
  • DERIVATIVES OF DOLAPROINE-DOLAISOLEUINE PEPTIDES
    Publication number: 20170190735
    Abstract: Provided are peptide analogs, pharmaceutical compositions comprising such compounds, and methods of treating cancer with such compounds.
    Type: Application
    Filed: May 27, 2015
    Publication date: July 6, 2017
    Applicant: AGENSYS, INC.
    Inventors: Brian Alan MENDELSOHN, Julien DUGAL-TERRIER, Stuart Daniel BARNSCHER
  • Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
    Patent number: 9617346
    Abstract: Antibodies and molecules derived therefrom that bind to novel STEAP-1 protein, and variants thereof, are described wherein STEAP-1 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, STEAP-1 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The STEAP-1 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with STEAP-1 can be used in active or passive immunization.
    Type: Grant
    Filed: January 23, 2015
    Date of Patent: April 11, 2017
    Assignee: AGENSYS, INC.
    Inventors: Aya Jakobovits, Soudabeh Etessami, Pia M. Challita-Eid, Juan J. Perez-Villar, Karen J. Morrison, Xiao-Chi Jia, Mary Faris, Jean Gudas, Arthur B. Raitano
  • ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS
    Publication number: 20160369003
    Abstract: Antibody drug conjugates (ADC's) that bind to 158P1D7 protein and variants thereof are described herein. 158P1D7 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in glioblastoma, lung cancer, bladder cancer, and breast cancer. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Application
    Filed: March 30, 2016
    Publication date: December 22, 2016
    Applicants: AGENSYS, INC., Seattle Genetics, Inc.
    Inventors: Robert Kendall MORRISON, Zili AN, Karen Jane Meyrick MORRISON, Josh SNYDER, Xiao-Chi JIA
  • Nucleic acid molecules encoding antibody drug conjugates (ADC) that bind to 191P4D12 proteins
    Patent number: 9314538
    Abstract: Antibody drug conjugates (ADC's) that bind to 191P4D12 protein and variants thereof are described herein. 191P4D12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Grant
    Filed: July 13, 2015
    Date of Patent: April 19, 2016
    Assignees: AGENSYS, INC., SEATTLE GENETICS, INC.
    Inventors: Daulet Satpayev, Robert Kendall Morrison, Karen Jane Meyrick Morrison, Jean Gudas, Aya Jakobovits, Michael Torgov, Zili An
  • Antibody drug conjugates (ADC) that bind to 161P2F10B proteins
    Patent number: 9308278
    Abstract: Antibody drug conjugates (ADC's) that bind to 161P2F10B protein are described herein. 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Grant
    Filed: December 13, 2013
    Date of Patent: April 12, 2016
    Assignee: Agensys, Inc.
    Inventors: Michael Torgov, Robert Kendall Morrison, Aya Jakobovits, Jean Gudas, Zili An
  • ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS
    Publication number: 20150306245
    Abstract: Antibody drug conjugates (ADC's) that bind to 191P4D12 protein and variants thereof are described herein. 191P4D12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Application
    Filed: July 13, 2015
    Publication date: October 29, 2015
    Applicants: AGENSYS, INC., SEATTLE GENETICS, INC.
    Inventors: Daulet SATPAYEV, Robert Kendall MORRISON, Karen Jane Meyrick MORRISON, Jean GUDAS, Aya JAKOBOVITS, Michael TORGOV, Zili AN
  • ANTIBODIES AND MOLECULES DERIVED THEREFROM THAT BIND TO STEAP-1 PROTEINS
    Publication number: 20150239986
    Abstract: Antibodies and molecules derived therefrom that bind to novel STEAP-1 protein, and variants thereof, are described wherein STEAP-1 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, STEAP-1 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer.
    Type: Application
    Filed: January 23, 2015
    Publication date: August 27, 2015
    Applicant: AGENSYS, INC.
    Inventors: Aya JAKOBOVITS, Soudabeh Etessami, Pia M. Challita-Eid, Juan J. Perez-Villar, Karen J. Morrison, Xiao-Chi Jia, Mary Faris, Jean Gudas, Arthur B. Raitano
  • Antibody drug conjugates (ADC) that bind to 191P4D12 proteins
    Patent number: 9078931
    Abstract: Antibody drug conjugates (ADC's) that bind to 191P4D12 protein and variants thereof are described herein. 191P4D12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: July 14, 2015
    Assignees: AGENSYS, INC., SEATTLE GENETICS, INC.
    Inventors: Daulet Satpayev, Robert Kendall Morrison, Karen Jane Meyrick Morrison, Jean Gudas, Aya Jakobovits, Michael Torgov, Zili An
  • Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
    Patent number: 9029516
    Abstract: Antibodies and molecules derived therefrom that bind to novel STEAP-1 protein, and variants thereof, are described wherein STEAP-1 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, STEAP-1 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The STEAP-1 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with STEAP-1 can be used in active or passive immunization.
    Type: Grant
    Filed: August 31, 2011
    Date of Patent: May 12, 2015
    Assignee: Agensys, Inc.
    Inventors: Aya Jakobovits, Soudabeh Etessami, Pia M. Challita-Eid, Juan J. Perez-Villar, Karen J. Morrison, Xiao-Chi Jia, Mary Faris, Jean Gudas, Arthur B. Raitano
  • Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
    Patent number: 9023605
    Abstract: Antibodies and molecules derived therefrom that bind to novel STEAP-1 protein, and variants thereof, are described wherein STEAP-1 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, STEAP-1 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The STEAP-1 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with STEAP-1 can be used in active or passive immunization.
    Type: Grant
    Filed: August 12, 2011
    Date of Patent: May 5, 2015
    Assignee: Agensys, Inc.
    Inventors: Aya Jakobovits, Soudabeh Etessami, Pia M. Challita-Eid, Juan J. Perez-Villar, Karen J. Morrison, Xiao-Chi Jia, Mary Faris, Jean Gudas, Arthur B. Raitano
  • Antibody drug conjugates (ADC) that bind to 158P1D7 proteins
    Patent number: 8968742
    Abstract: Antibody drug conjugates (ADC's) that bind to 158P1D7 protein and variants thereof are described herein. 158P1D7 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in glioblastoma, lung cancer, bladder cancer, and breast cancer. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Grant
    Filed: August 23, 2013
    Date of Patent: March 3, 2015
    Assignee: Agensys, Inc.
    Inventors: Robert Kendall Morrison, Zili An, Karen Jane Meyrick Morrison, Josh Snyder, Xiao-Chi Jia
  • Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers
    Patent number: 8951744
    Abstract: The invention described herein relates to novel nucleic acid sequences and their encoded proteins, referred to as 158P1D7 and variants thereof, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express 158P1D7 and variants thereof.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: February 10, 2015
    Assignee: Agensys, Inc.
    Inventors: Aya Jakobovits, Robert Kendall Morrison, Arthur B. Raitano, Pia M. Challita-Eid, Juan J. Perez-Villar, Karen Jane Meyrick Morrison, Mary Faris, Wangmao Ge, Jean Gudas, Steven B. Kanner
  • Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers
    Patent number: 8945570
    Abstract: The invention described herein relates to novel nucleic acid sequences and their encoded proteins, referred to as 158P1D7 and variants thereof, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express 158P1D7 and variants thereof.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: February 3, 2015
    Assignee: Agensys, Inc.
    Inventors: Aya Jakobovits, Robert Kendall Morrison, Arthur B. Raitano, Pia M. Challita-Eid, Juan J. Perez-Villar, Karen Jane Meyrick Morrison, Mary Faris, Wangmao Ge, Jean Gudas, Steven B. Kanner
  • Prostate stem cell antigen (PSCA) variants and subsequences thereof
    Patent number: 8853364
    Abstract: PSCA and its encoded protein, and variants thereof, are described wherein PSCA exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, PSCA provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The PSCA gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with PSCA can be used in active or passive immunization.
    Type: Grant
    Filed: September 17, 2009
    Date of Patent: October 7, 2014
    Assignee: Agensys, Inc.
    Inventors: Wangmao Ge, Pia M. Challita-Eid, Arthur B. Raitano, Aya Jakobovits
  • Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
    Patent number: 8846043
    Abstract: A novel gene 0161P2F10B (also designated 161P2F10B) and its encoded protein, and variants thereof, are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 161P2F10B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 161P2F10B gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 161P2F10B can be used in active or passive immunization.
    Type: Grant
    Filed: October 21, 2013
    Date of Patent: September 30, 2014
    Assignee: Agensys, Inc.
    Inventors: Aya Jakobovits, Arthur B. Raitano, Mary Faris, Rene S. Hubert, Wangmao Ge, Karen Jane Meyrick Morrison, Robert Kendall Morrison, Pia M. Challita-Eid
  • Antibodies to tumor associated proteins
    Patent number: 8779111
    Abstract: A novel gene 024P4C12 (also designated 24P4C12) and its encoded protein, and variants thereof, are described wherein 24P4C12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 24P4C12 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 24P4C12 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 24P4C12 can be used in active or passive immunization.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: July 15, 2014
    Assignee: Agensys, Inc.
    Inventors: Arthur B. Raitano, Karen Jane Meyrick Morrison, Wangmao Ge, Pia M. Challita-Eid, Aya Jakobovits